CN1178673A - External use liniment for curing dermatosis - Google Patents
External use liniment for curing dermatosis Download PDFInfo
- Publication number
- CN1178673A CN1178673A CN 97106692 CN97106692A CN1178673A CN 1178673 A CN1178673 A CN 1178673A CN 97106692 CN97106692 CN 97106692 CN 97106692 A CN97106692 A CN 97106692A CN 1178673 A CN1178673 A CN 1178673A
- Authority
- CN
- China
- Prior art keywords
- grams
- gram
- externally
- pharmaceutical formulation
- applied liniment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The liniment consists of medicine and dispersing menstruum and has two recipe. In Recipe A, the medicine consists of benzocaine or dycloninum, resorcind, carbolic acid, chlorpheniramine and alum; and the dispersing menstruum consists of absolute ethyl alcohol, glycerol, boric acid and distilled water. In Recipe B, medicine consists of benzocaine or dycloninum, clotrimazole, chlorpheniramine and alum; and the dispersing menstruum consists of glycerol and distilled water. The present invention features that it compounds medicine with high cure effect and no hormone by using cheap material.
Description
The present invention relates to a kind of medicinal preparation, be specifically related to the dermopathic suspension type of a kind of treatment externally-applied liniment, also claim neurodermatitis wet mode liniment.
Dermatosiss such as the psoriasis that human body skin is caused by allergy, abnormal cell hypertrophy, contact allergy, physical stimulation, courses of infection etc. (drop shape), seborrheic dermatitis, insect dermatitis, detergent dermatitis, gold finger-ring dermatitis, hair dye dermatitis, eczema capitis, eczema scrotum, anal eczema, eczema tyloticum, eczema lichenoides, tinea manuum eczematization, tinea pedis eczematization, prurigo nodularis and pubic louse mostly are obstinate obstinate disease greatly, make troubles for for a long time many patients even misery.The medicament categories of treatment this respect disease is a lot of both at home and abroad at present, and curative effect has his own strong points.But these medicines generally contain corticosteroid hormone, have in addition in antifungal drug, mix 17-hydroxy-11-dehydrocorticosterone.The shortcoming of this class medicine is: 1. effective during medication, bounce after the drug withdrawal, and belong to a kind of acts and efforts for expediency curative effect fully, be difficult to cure; 2. because the protopathy that disease is constrained in short-term by 17-hydroxy-11-dehydrocorticosterone institute can very fast recurrence, cause new steroid dermatitis, not only make disease control difficult for a long time but also may increase the weight of the state of an illness, even the generation serious consequence.Therefore the present invention is the drawback that overcomes many hormones dermatosis treating medicines, on the pathogenetic basis of the above-mentioned dermatosis of further investigation, makes great efforts to explore a kind of new external use medicine for treating dermatosis that adopts several active component reasonable compatibilities to form.
The purpose of this invention is to provide and a kind ofly not contain that any corticosteroid hormone and good effect, cure rate height, relapse rate are low, few side effects, dermatosis externally-applied liniment (also claiming neurodermatitis wet mode liniment) that cost is low.
For achieving the above object, the technical solution used in the present invention first is: the dermopathic externally-applied liniment of a kind of treatment, and described externally-applied liniment is synthetic by pharmaceutical formulation and dispersion medium solvent, and every hectogram contains in the described pharmaceutical formulation:
Benzocaine or dyclonine 0.2 gram～16 grams;
Resorcin 3 grams～45 grams;
Carbolic acid 3 grams～45 grams;
Chlorphenamine 0.2 gram～16 grams;
Alumen 1 gram～20 grams.
In the technique scheme first, every hectogram further contains Borneolum Syntheticum or Mentholum 1 gram～20 grams in the described pharmaceutical formulation.
In the technique scheme first, every hectogram contains in the described dispersion medium solvent:
Dehydrated alcohol 1.2 grams～20 grams;
Glycerol 4 grams～30 grams;
Boric acid 0.4 gram～10 grams;
Distilled water 40 grams～80 grams.
In the technique scheme first, the weight ratio of described pharmaceutical formulation and dispersion medium solvent is 1: 2.5～1: 5.
For achieving the above object, the technical solution used in the present invention second is: the dermopathic externally-applied liniment of a kind of treatment, and described externally-applied liniment is synthetic by pharmaceutical formulation and dispersion medium solvent, and every hectogram contains in the described pharmaceutical formulation:
Benzocaine or dyclonine 0.5 gram～40 grams;
Clotrimazole 1 gram～60 grams;
Chlorphenamine 0.1 gram～15 grams;
Alumen 1 gram～45 grams.
In the technique scheme second, every hectogram further contains Borneolum Syntheticum or Mentholum 1 gram～45 grams in the described pharmaceutical formulation.
In the technique scheme second, every hectogram contains in the described dispersion medium solvent:
Glycerol 20 grams～40 grams;
Distilled water 60 grams～80 grams.
Boric acid 0～10 gram.
In the technique scheme second, the weight ratio of described pharmaceutical formulation and dispersion medium solvent is 1: 3～1: 6.
The present invention gives one's full attention to the human body skin characteristics different to Drug tolerance of different parts, the eczema scrotum of oozing out for psoriasis, neurodermatitis, seborrheic dermatitis, the hair dye dermatitis and having of treatment facial area, become the patient of the tinea pedis eczematization of pus, do not use the technical scheme first that contains resorcin, two kinds of zest components of carbolic acid, and the technical scheme second that adopts non-irritating clotrimazole to replace resorcin and carbolic acid component to be constituted, with the adverse consequences that prevents to occur.Therefore the technical scheme first and the technical scheme second main distinction in the use are the skin table situations of the disease sites and the disease sites of human body skin.Be specially: psoriasis belong to erythrodermic, pustule type, general hair style, pattern, parapsoriasis patient, operation technique scheme first not; Neurodermatitis is must share with its medicine to obtain good effect not in technical scheme first indication; Seborrheic dermatitis betides facial area, not operation technique scheme first; Hair dye dermatitis is involved not operation technique scheme first of facial area; Eczema scrotum companion oozes out, rotten to the corn, when chapping, operation technique scheme first not; Anal eczema companion oozes out, rotten to the corn, chap or accompany pruritus vulvae, not operation technique scheme first simultaneously; The eczema tyloticum place of chapping is operation technique scheme first not; Acute the oozing out and the place that chaps, not operation technique scheme first of tinea manuum eczematization companion; The inflammation of tinea pedis eczematization companion ulcer, erosion, not operation technique scheme first.
In the technical scheme first of the present invention, persistent antipruritic, the analgesic activity of benzocaine or dyclonine tool is suitable for pudendum and anal eczema especially, can form semi-solid agglomerate though meet resorcin, participates in so can neutralize because of other medicines are arranged; Resorcin tool sterilization, antipruritic, astriction, it is used for the treatment of eczema, psoriasis, seborrheic dermatitis bright year of China's " pharmacopeia "; Carbolic acid tool kill bacteria and spore also play antisepsis; The Alumen tool dampness insecticidal action of reducing phlegm and internal heat, detoxify, what the technical program first was used can separate the strong of resorcin, carbolic acid; Borneolum Syntheticum or the antiinflammatory of Mentholum tool, detumescence, itching-relieving action, modern pharmacology disclose its again tool press down the effect of antifungal, though water insoluble, then liquefiable of carbolic acid; Chlorphenamine tool antagonism allergy, the effect of inhibition Mastocytosis, but always be usually used in taking orally, the present invention is with its external, not only as ingredient but also as preventing because of using this liniment may cause the restriction medium of skin allergy.
In the technical solution of the present invention second, clotrimazole has good inhibitory or killing effect to various candidiasises, neogenesis cryptococcus, phycomycete, mycete etc., yet because of its curative effect at different parts has different, clinical in seldom using it, the technical program second is with itself and its medicine compatibility, remedy deficiency, received satisfied effect; Clotrimazole is water insoluble in addition, is coated with easily to come off after putting on the skin, but under the glycerol effect in dispersion medium, then can keep its drug powder here being coated with the skin surface of putting on the skin.
The present invention's advantage compared with prior art is: 1. do not contain the hormones composition, and the cure rate height, relapse rate is low, and is widely applicable, has no side effect, easy to use.2. preparation technology is simple, and technology is grasped easily.3. pharmaceutical properties is stable, never degenerates, and is pollution-free.4. small investment, instant effect, return rate height.
Now that externally-applied liniment clinical case curative effect situation statistics of the present invention is as follows:
Sick class sum (people) is cured (people) effectively (people) invalid (people)
Psoriasis 16 79
Seborrheic dermatitis 18 16 2
Insect dermatitis 44 44
Detergent dermatitis 96 96
Gold finger-ring dermatitis 39 39
Hair dye dermatitis 18 17 1
Eczema capitis 33 33
Eczema scrotum 47 47
Anal eczema 68 68
Eczema tyloticum 13 11 2
Eczema lichenoides 22 19 3
Tinea manuum eczematization 113 113
Tinea pedis eczematization 84 84
Prurigo nodularis 47 45 2
Pubic louse 15 15
Below in conjunction with embodiment the present invention is further described:
Embodiment one: the dermopathic externally-applied liniment of a kind of treatment (technical scheme first), and described externally-applied liniment is synthetic by pharmaceutical formulation and dispersion medium solvent, and every hectogram contains in the described pharmaceutical formulation:
Benzocaine 10 grams;
Resorcin 30 grams;
Carbolic acid 30 grams;
Chlorphenamine 10 grams;
Alumen 10 grams;
Borneolum Syntheticum 10 grams.
Every hectogram contains in the described dispersion medium solvent:
Dehydrated alcohol 10 grams;
Glycerol 15 grams;
Boric acid 5 grams;
Distilled water 70 grams.
The weight ratio of described pharmaceutical formulation and dispersion medium solvent is 1: 3.
Pharmaceutical formulation is prepared the back by said ratio pulverize, the dispersion medium solvent is prepared by said ratio, mix and stir getting final product then by described weight ratio.
Embodiment two: the dermopathic externally-applied liniment of a kind of treatment (technical scheme second), and described externally-applied liniment is synthetic by pharmaceutical formulation and dispersion medium solvent, and every hectogram contains in the described pharmaceutical formulation:
Benzocaine 15 grams;
Clotrimazole 50 grams;
Chlorphenamine 5 grams;
Alumen 15 grams;
Borneolum Syntheticum 15 grams.
Every hectogram contains in the described dispersion medium solvent:
Glycerol 22 grams;
Distilled water 75 grams;
Boric acid 3 grams.
The weight ratio of described pharmaceutical formulation and dispersion medium solvent is 1: 4.
Pharmaceutical formulation is prepared the back by said ratio pulverize, the dispersion medium solvent is prepared by said ratio, mix and stir getting final product then by described weight ratio.
Claims (10)
1. treat dermopathic externally-applied liniment for one kind, it is characterized in that: described externally-applied liniment is synthetic by pharmaceutical formulation and dispersion medium solvent, and every hectogram contains in the described pharmaceutical formulation:
Benzocaine or dyclonine 0.2 gram～16 grams;
Resorcin 3 grams～45 grams;
Carbolic acid 3 grams～45 grams;
Chlorphenamine 0.2 gram～16 grams;
Alumen 1 gram～20 grams.
2. externally-applied liniment according to claim 1 is characterized in that: every hectogram further contains Borneolum Syntheticum 1 gram～20 grams in the described pharmaceutical formulation.
3. externally-applied liniment according to claim 1 is characterized in that: every hectogram further contains Mentholum 1 gram～20 grams in the described pharmaceutical formulation.
4. externally-applied liniment according to claim 1 is characterized in that: every hectogram contains in the described dispersion medium solvent:
Dehydrated alcohol 1.2 grams～20 grams;
Glycerol 4 grams～30 grams;
Boric acid 0.4 gram～10 grams;
Distilled water 40 grams～80 grams.
5. externally-applied liniment according to claim 1 is characterized in that: the weight ratio of described pharmaceutical formulation and dispersion medium solvent is 1: 2.5～1: 5.
6. treat dermopathic externally-applied liniment for one kind, it is characterized in that: described externally-applied liniment is synthetic by pharmaceutical formulation and dispersion medium solvent, and every hectogram contains in the described pharmaceutical formulation:
Benzocaine or dyclonine 0.5 gram～40 grams;
Clotrimazole 1 gram～60 grams;
Chlorphenamine 0.1 gram～15 grams;
Alumen 1 gram～45 grams.
7. externally-applied liniment according to claim 6 is characterized in that: every hectogram further contains Borneolum Syntheticum or Mentholum 1 gram～45 grams in the described pharmaceutical formulation.
8. externally-applied liniment according to claim 6 is characterized in that: every hectogram contains in the described dispersion medium solvent:
Glycerol 20 grams～40 grams;
Distilled water 60 grams～80 grams.
9. externally-applied liniment according to claim 8 is characterized in that: every hectogram further contains boric acid 0～10 gram in the described dispersion medium solvent.
10. externally-applied liniment according to claim 6 is characterized in that: the weight ratio of described pharmaceutical formulation and dispersion medium solvent is 1: 3～1: 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97106692A CN1063632C (en) | 1997-10-30 | 1997-10-30 | External use liniment for curing dermatosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97106692A CN1063632C (en) | 1997-10-30 | 1997-10-30 | External use liniment for curing dermatosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1178673A true CN1178673A (en) | 1998-04-15 |
| CN1063632C CN1063632C (en) | 2001-03-28 |
Family
ID=5168908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97106692A Expired - Fee Related CN1063632C (en) | 1997-10-30 | 1997-10-30 | External use liniment for curing dermatosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1063632C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103705552A (en) * | 2013-12-26 | 2014-04-09 | 福建金源泉科技发展有限公司 | External liniment with function of improving allergy |
| CN105998150A (en) * | 2016-07-23 | 2016-10-12 | 万强胜 | Neurodermatitis treating medicine |
| CN106334144A (en) * | 2016-08-26 | 2017-01-18 | 王立平 | External use medicine for treating skin diseases |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1032117C (en) * | 1989-11-21 | 1996-06-26 | 中国人民解放军军事医学科学院毒物药物研究所 | Process for phthiobuzonum compound liniment |
| CN1081878A (en) * | 1993-06-16 | 1994-02-16 | 中国人民解放军军事医学科学院毒物药物研究所 | A kind of medicine for the treatment of tinea and pruritus |
-
1997
- 1997-10-30 CN CN97106692A patent/CN1063632C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103705552A (en) * | 2013-12-26 | 2014-04-09 | 福建金源泉科技发展有限公司 | External liniment with function of improving allergy |
| CN103705552B (en) * | 2013-12-26 | 2016-03-16 | 福建金源泉科技发展有限公司 | A kind of have the externally-applied liniment improving irritated function |
| CN105998150A (en) * | 2016-07-23 | 2016-10-12 | 万强胜 | Neurodermatitis treating medicine |
| CN106334144A (en) * | 2016-08-26 | 2017-01-18 | 王立平 | External use medicine for treating skin diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1063632C (en) | 2001-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1032900C (en) | Metrohidazole formulations and therapeutical uses thereof | |
| CN1241578C (en) | Skin-care medicine with functions of relieving-itching, fully eliminating-toxins and curing-tinea, and its prepn. method | |
| CN1308027C (en) | Medicinal formulation for treating skin tinea | |
| CN1903289A (en) | Gel for treating hemorrhoidal anus and rectum diseases, and its prepn. method | |
| CN1063632C (en) | External use liniment for curing dermatosis | |
| CN1251738C (en) | Chinese medicine for treating ashen nail and its preparation method | |
| CN1990045A (en) | Highly effective plaster for burn and scald and its preparation process | |
| CN1101214C (en) | External use disinfectant anagesic and production thereof | |
| CN1245074A (en) | Medicine for reducing acidity in vegina and its usage | |
| CN101040957A (en) | Medicine for treating skin diseases such as eczema and dermatitis and the method for preparing the same | |
| CN103520262B (en) | A kind of lipid soluble gynecological gel | |
| CN1850100A (en) | Medicinal composition for treating vagina disease | |
| CN1771937A (en) | Externally applied podophyllotoxin ointment and its prepn | |
| CN1233312C (en) | Liposome anti-fungus medication sprayer formulation | |
| CN1193779C (en) | Vagina cleaning and antiphlogistic suppository and its preparing method | |
| CN102008586A (en) | Effective drug for treating skin disease | |
| CN1244398A (en) | Improved tincture with both Chinese and Western medicines for dermatomycosis | |
| CN1293893C (en) | Gel of Chinese traditional medicine and preparation method | |
| CN100340263C (en) | Suppository for treating bacterial vaginitis | |
| CN1644206A (en) | Medicine for treating tinea containing biological alkaline salt and preparation thereof | |
| CN1706462A (en) | Acne eliminating tablet and its prepn process | |
| CN1857276A (en) | Medicine composition for treating valval and/or vaginal diseases | |
| CN1431008A (en) | Medicine for treating various fungal skin disease or bromidrosis | |
| CN1272012C (en) | Dermatopathy therapeutic medicine compositions and its preparation method | |
| CN100337669C (en) | Externally applied medicine for curing pain and process for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |